Bank of America lowered ABBV price target to $233, but HSBC raised it to $265, reflecting mixed analyst sentiment due to transition from Humira to Skyrizi and Rinvoq, which generated $18.5 billion in sales in 2025. ABBV is a global biopharmaceutical company with diverse therapies in immunology, oncology, neuroscience, and aesthetics markets. Looking for an AI stock with promising returns? Check out our report on the cheapest AI stock with 10,000% upside potential.

Read more at Yahoo Finance: Analysts Split on AbbVie Inc. (ABBV) as BofA Cuts Target and HSBC Turns Bullish